WHO ICTRP trial
A clinical trial to check if combination therapy of osimertinib plus platinum…
CTRI/2020/06/025980 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2020/06/025980 |
|---|---|
| Public title | A clinical trial to check if combination therapy of osimertinib plus platinum plus pemetrexed is better than monotherapy (osimertinib) for patient with Epidermal growth factor receptor positive Locally Advance or Metastatic Non- small Cell Lung Cancer. |
| Scientific title | A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation- Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2) |
| Primary sponsor | AstraZeneca AB |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | Argentina;Australia;Brazil;Canada;Chile;China;Czech Republic;Democratic People's Republic of Korea;France;India;Japan;Peru;Philippines;Russian Federation;Slovakia;South Africa;Taiwan;Thailand;United… |
| Conditions | Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung |
| Interventions | Intervention1: Osimertinib with Cisplatin or Carboplatin plus Pemetrexed: 1:1Assignment Control Intervention1: Osimertinib: Monotherapy |
| Registration date | Jun 18, 2020 |
| Target size | 556 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: